NEWS & EVENTS

 

IONTAS to Generate Antibodies using Mammalian Display Technology for a Global Biopharma

 
IONTAS to Generate Antibodies using Mammalian Display Technology for a Global Biopharma

23 January 2018

IONTAS Limited has announced that it has signed an agreement with Sanofi to discover antibodies using IONTAS’ proprietary Mammalian Display Technology.

IONTAS’ platform allows for the construction of large libraries of monoclonal cell lines each displaying a different IgG-formatted antibody on the cell surface. Novel binders can be isolated from the libraries by using fluorescence-activated cell sorting on the basis of antigen binding. The system also has the potential to identify clones with development liabilities, such as self-aggregation, during the initial discovery phase.

IONTAS are a biotechnology company focused on antibody discovery and cutting-edge technology development. They are a leader in the discovery and optimisation of fully human antibodies.

Read the full press release.

Partner Nick Sutcliffe and associate Rachel Jones work with IONTAS on their IP portfolio.